Clinical Trial Update: A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT) [Phase 2]

View source ↗

Summary

This completed Phase 2 trial evaluated the efficacy and safety of twice-daily cinacalcet (AMG 073) in patients with primary hyperparathyroidism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• cinacalcet (cinacalcet hydrochloride)

Snippet

Sponsor: Amgen | Conditions: Hyperparathyroidism, Primary | Phase 2 | Status: COMPLETED